ReviewFrontiers in bioengineering and biotechnology2025
The role of collagen and collagen I/III ratio in pathological conditions: insights into molecular mechanisms and therapeutic approaches.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Depot-specific differences in visceral and subcutaneous adipose tissue from patients with obesity.Adipocyte · 2026Article
- Surgical Complexity and Postoperative Outcomes in Recurrent Versus Primary Incisional Hernias Following Elective Retromuscular Repair: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Promotion of DFU Wound Healing via BRG1-COL16A1 Axis in Fibroblasts.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ultradeformable Vesicles for Wound Healing: Ethosomes, Transferosomes, and Transethosomes in Topical Drug Delivery.Pharmaceutics · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagen is the predominant structural protein, contributing to 25%-30% of total body protein. It is vital for maintaining the strength, flexibility, and structural integrity of connective tissues throughout the human body. Of the 28 identified collagen types, collagen I and collagen III are especially critical - collagen I imparts tensile strength, while collagen III enhances matrix flexibility. Disruptions in collagen structure and composition are frequently associated with aberrant collagen I and collagen III ratio that compromises tissue functions and contributes to pathological conditions affecting bone (osteoporosis), oral tissues (periodontal disease), wound healing (diabetic complications), reproductive organs (ovarian cancer), and pelvic support structures (pelvic organ prolapse), among others. These alterations arise from aging, genetic polymorphisms, and disease factors that disrupt collagen synthesis, assembly, and degradation. This review highlights recent advances in understanding the role of collagen and collagen I/III ratio in pathophysiological processes and deliberates emerging therapeutic interventions designed to restore collagen equilibrium, encompassing biomaterials, stem cell therapies, gene editing techniques, and biophysical stimulation modalities. Future directions in tissue-engineered extracellular matrix development, precision medicine applications, and combined therapeutic strategies are discussed as transformative approaches for managing collagen-associated disorders and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.